All these findings not only illuminated the unique TIME of HRD and HRP tumors but also proposed precise targeted therapies, aside from PARPis and anti‐PDCD1 antibodies, for HRD and HRP patients respectively, laying the framework for future clinical trials. Here, PDCD1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.